Metastatic Hormone-Sensitive Prostate Cancer, mHSPC
Conditions
Interventions
Goserelin Microspheres + Abiraterone:None
Goserelin Sustained-Release Implant + Abiraterone Combination:None
Sponsors
The First Affiliated Hospital of Xi'an Jiaotong University
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: 1.Pathologically diagnosed PCa patients; 2.mHSPC patients confirmed by imaging (PET/CT, whole - body bone ECT, prostate MRI) and serum tests; 3.mHSPC patients initially treated with goserelin and abiraterone as first - line therapy; 4.mHSPC patients who can receive at least 4 cycles of goserelin and abiraterone; 5.Patients who can provide complete medical and follow - up records.
Exclusion criteria
Exclusion criteria: 1.PCa patients without pathological diagnosis; 2.mHSPC patients treated with other endocrine drugs before or during treatment; 3.mHSPC patients who have had surgical castration; 4.mHSPC patients who relapsed after prostatectomy; 5.Patients who can't or refuse to complete clinical data collection or follow - up; 6.Patients allergic to LHRH, its analogs, or goserelin; 7.Patients with other primary tumors; 8.Patients with other severe organ diseases.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Serum PSA;Testosterone;Abiraterone concentration; | — |
Countries
China
Contacts
Public ContactLi Houli
The First Affiliated Hospital of Xi'an Jiaotong University
Outcome results
None listed